Resources

Cancer Research Horizons launches the Cancer Impact Club, a community of business builders whose philanthropy, expertise and networks will help shape the future of cancer treatment.

University of Oxford spinout accelerates commercial expansion in the US of its innovative stroke AI imaging solution, with its demonstrated impact on vital treatments.

Maxion Therapeutics (”Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, announced today that it has raised $72 million (£58 million) in a Series A financing.

The 2024 Bionow Awards dinner marked an exceptional evening of recognition and celebration, as 342 distinguished guests gathered at the Concorde Conference Centre on 6 March to honour those who have demonstrated outstanding ingenuity and dedication.

Arecor establishes partnership with biopharmaceutical company to develop novel formulation of peptide therapy.

TRIMTECH Therapeutics raises $31 million seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases.

Dr Danuta Jeziorska outlines that the UK has a unique opportunity to lead in genomics and AI-driven precision medicine, but a critical early-stage funding gap—particularly for drug target discovery companies—threatens its global competitiveness.

Stablepharma Ltd has secured a €2.5 million EIC Accelerator grant, recognizing its pioneering fridge-free pharmaceutical technology.

In this article, Giuseppe Amoroso, R&D Tax Advisor for biotech companies, explores the critical role of R&D tax compliance in the biotechnology sector.

Prostate cancer is the most common cancer among men, with over 136 new diagnoses in the UK each day. Stratosvir, a leading company in viral immunotherapy, is changing the landscape of treatment.

As Donald Trump returns to the White House, the biotech industry is assessing what his presidency means for investment and innovation. With the UK’s life sciences sector gaining strength, could this be the moment to turn uncertainty into opportunity?

This week our new BIA UK biotech financing report shows £3.5 billion invested in 2024, I detail the launch of the STVC Fellowship, look at the impact of the proposed US withdrawal from WHO, and news from Davos on groundbreaking AI-driven drug trials by Isomorphic Labs.

The UK biotech sector soared in 2024, raising £3.5 billion—a 94% surge—evidencing its resilience, global appeal, and untapped potential for UK investors amidst calls for pension reform.

The British Business Bank celebrates a decade of transformative impact with its Power of 10: 10-Year Impact Report.

In this article, Dr. Fawzi Abou-Chahine, Grants Director at FI Group UK, delves into the evolving landscape of grant funding in the biotechnology sector.

Glox Therapeutics wins £500,000 from LifeArc’s Collaborative Discovery Programme to fast-track precision antibiotics tackling antimicrobial-resistant lung infections in cystic fibrosis patients.

£20 million Series A financing underway to support development of lead product